A clinical trial conducted by Prof. Alexandra Durr's team (Sorbonne University.AP-HP) at the Paris Brain Institute and the Pitié-Salpêtrière Hospital AP-HP shows that despite the hopes raised in ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Riluzole did not improve clinical or ...

Adult-onset SCA2 is characterized by progressive ataxia, extremely slow saccades, dysarthria, supranuclear ophthalmoplegia, cognitive impairment, peripheral neuropathy, as well as action or postural ...

SALT LAKE CITY - Scientists report a significant step toward combatting two degenerative brain diseases that chip away at an individual's ability to move, and think. A targeted therapy developed by ...

An expanded repeat region in the ataxin-2 gene causes spinocerebellar ataxia or boosts risk for amyotrophic lateral sclerosis, leading scientists to believe it was only a matter of time before they ...

A drug, engineered to combat the gene that causes spinocerebellar ataxia type 2 (SCA2), might also be used to treat amyotrophic lateral sclerosis (ALS), researchers have demonstrated in two studies of ...

When he discovered the gene, Dr. Stefan Pulst thought the therapy would come quickly but finding the gene was only the beginning of the journey. After meeting a family with a different type of nervous ...

A defective response to DNA damage is observed in several human autosomal recessive ataxias with oculomotor apraxia, including ataxiatelangiectasia. We report that senataxin, defective in ataxia ...

A team led by Specially Appointed Associate Professor Tomohiko Ishihara and Professor Osamu Onodera at Niigata University, along with Professor Yoshitaka Nagai at Kindai University, conducted a ...

Scientists report a significant step toward combatting two degenerative brain diseases that chip away at an individual's ability to move, and think. A targeted therapy developed by investigators at ...